Mysimba (Bupropion Hydrochloride, Naltrexone Hydrochloride)

The combination works by modulating the hypothalamic melanocortin pathway. Bupropion inhibits the reuptake of norepinephrine and dopamine, stimulating POMC neurons that reduce appetite. Naltrexone blocks opioid receptors that normally provide feedback inhibition to those neurons, prolonging the appetite‑suppressing signal and increasing energy expenditure.

The dosing regimen for Mysimba is individualized by the prescribing clinician based on the patient’s medical history, tolerability, and treatment response. The prescriber determines the appropriate titration schedule and maintenance dose, which should be followed exactly as instructed.

Safety data for Mysimba in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional after a thorough risk‑benefit assessment.

To request Mysimba, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials. After verification, the team provides pricing, availability, shipping details (including any special handling) and assists with import documentation.

Mysimba differs from GLP‑1 receptor agonists such as liraglutide or semaglutide, which act primarily through gastrointestinal mechanisms and glucose regulation. Mysimba’s dual central‑acting mechanism targets appetite and energy expenditure via the melanocortin pathway, offering an alternative for patients who may not tolerate injectable therapies or who prefer an oral option.

Mysimba tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and keep out of reach of children. Do not store in bathrooms or other humid environments.

Mysimba is taken orally as whole tablets with water. The usual practice is to start with a low dose and titrate upward over several weeks, as directed by the prescriber, to minimise side effects. It should be taken with or without food, according to the clinician’s instructions.

Serious risks include seizures, significant increases in blood pressure, suicidal thoughts or other severe psychiatric changes, and rare but severe allergic reactions such as anaphylaxis. Patients should be monitored closely for these events, especially during dose escalation, and seek immediate medical attention if they occur.

Mysimba is contraindicated in individuals with a known hypersensitivity to bupropion, naltrexone, or any tablet components; those currently using monoamine oxidase inhibitors; patients with uncontrolled hypertension; a history of seizures; or who are pregnant or breastfeeding unless the prescriber determines the benefit outweighs the risk.